aboBoNT/A	abobotulinum neurotoxin type A
ADOSE(uDU)	dose at investigation (actual dose)
AGE(years)	age at recruitment
AOS(years)	age at onset of symptoms
AOT	age at onset of therapy
ASCD	actual severity of CD
ATSUI	TSUI at investigation (actual TSUI)
BoNT	botulinum neurotoxin
CD	cervical dystonia
CO	continuous onset subgroup
CoD	course of the severity of CD
CoDA	CoD after BoNT therapy
CoDB	CoD before BoNT therapy
CR	continuous response subgroup
CSTF	complete STF
DO	delayed onset subgroup
DR	delayed response subgroup
DURS (months)	time from onset of symptoms to BoNT therapy
DURT (months)	duration of BoNT therapy
FSPP	mean frequency of different symptoms
FSPP-A	mean frequency of different symptoms during the last month before recruitment
NSPP-B	mean frequency of different symptoms before onset of BoNT therapy
GCP	good clinical practice
IDOSE(uDU)	dose at onset of BoNT therapy
IMPD	improvement according to drawing (for details see Methods)
IMPQ	improvement according to questionnaire
IMPTSUI	improvement according to TSUI score
incoBoNT/A	incobotulinum neurotoxin type A
INDOSE(uDU)	increase of dose during BoNT therapy
ITSUI	TSUI score at onset of BoNT therapy
MHDA	mouse hemidiaphragm assay
onaBoNT/A	onabotulinum neurotoxin type A
MV	mean value
OO	other onset subgroup (for details see Methods)
OR	other response subgroup (for details see Methods)
RO	rapid onset subgroup
RR	rapid response subgroup
rimaBoNT/B	rimabotulinum neurotoxin type B
SD	standard deviation
STF	secondary treatment failure
STFG	subgroup of patients drawing a CoD typical for a secondary treatment failure
TSUI	TSUI score
uDU	unified dose units